Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

Bris­tol My­ers Squibb’s at­tempt to turn Coben­fy in­to a megablock­buster neu­ro­science drug ran in­to a stum­bling block Tues­day af­ter­noon.

The com­pa­ny said Coben­fy, ap­proved last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER